Abstract:Abstract Breast Cancer is the most common cancer diagnosed in women in the United States. Second only to lung cancer, breast cancer results in the greatest number of cancer deaths for women. Hormone receptor positive (HR+) breast cancers - cancers expressing the nuclear receptors for steroid hormones estrogen and progesterone, termed the estrogen receptor (ER) and progesterone receptor (PR) - make up the largest proportion of diagnosed breast cancers by a significant margin. So, although the HR+ subtype is less aggressive compared to others, it continues to be the largest contributor to breast cancer mortality. Treatment consists of anti-endocrine therapies, largely targeting ER/estrogen, the established drivers of breast cancer growth. Most women respond well to these therapies, but for women who do not, there are few alternative options. With the advent of immunotherapy and its successes in treating and controlling certain tumor types, many were hopeful that it could be employed for breast cancer as well. However, breast cancers, especially HR+ breast cancers, are considered “immune cold.” They lack high proportions of tumor-infiltrating lymphocytes (TILs), have low neoantigen production, and high percentages of immunosuppressive cells. A contributing factor could be the hormones present in the tumor microenvironment. The accepted paradigm is that lifetime exposure to estrogens drives the development of HR+ breast cancer, but both estrogen and progesterone are part of the normal menstrual cycle. Prior work from our lab has uncovered a novel immune-modulatory role for progesterone, pivotal to promoting the growth of PR-positive mammary tumors. Recent preliminary data from our lab show that progesterone treatment conveys immune protection against T cell killing in a co-culture with E0771 mammary gland tumor cells. However, when activated in monoculture, T cells exposed to increasing concentrations of progesterone have no differing expression of cell surface activation or exhaustion markers, implying that progesterone is not eliciting this effect by interfering with the T cell activation cascade nor is it inducing premature exhaustion. Interestingly, progesterone treatment instead leads to a concentration-dependent increase in T cell death compared to the untreated control. In vivo, these results are supported as progesterone treatment decreases the amount of total CD3+ T cells, and specifically the cytotoxic CD8+ subset, in the mammary glands of mice. These results suggest that progesterone could modulate the breast and tumor microenvironment, providing tumor cells with protection from immunosurveillance and contributing to HR+ breast cancer development. These data also argue for the use of anti-progestins to be added to the HR+ breast cancer treatment regimen to boost anti-tumor immune activity. Citation Format: Amanda Heard, Lauryn R. Werner, Eilidh I. Chowanec, Harmony Saunders, Julio Tinoco, Zachary C. Hartman, Christy R. Hagan. Progesterone promotes immunosuppression in the murine mammary gland by causing T cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6877.

Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine

Progesterone Induces Pyroptosis Of P53-Defective Fimbrial Epithelial Cells Through The Paracrine By Stromal Fibroblast

Inhibiting 3βhsd1 to Eliminate the Oncogenic Effects of Progesterone in Prostate Cancer

Follicular Fluid Progesterone Downregulated HPGD and COX2 in Granulosa Cells Via Suppressing NF-ĸB in Endometriosis

Progesterone limits the tumor-promoting effects of the beta-subunit of human chorionic gonadotropin via non-nuclear receptors

Abstract 3666: Follicle-stimulating Hormone Inhibits Apoptosis and Autophagy in Ovarian Cancer Cells by Activating Survivin and Rab25

Molecular Mechanism of Mercuric Chloride Inhibiting Progesterone Secretion in Ovarian Granulosa Cells of Laying Hens

Hyaluronic Acid Prevents Immunosuppressive Drug-Induced Ovarian Damage Via Up-Regulating PGRMC1 Expression

Goserelin Promotes the Apoptosis of Epithelial Ovarian Cancer Cells by Upregulating Forkhead Boxï¿½o1 Through the PI3K/AKT Signaling Pathway

SOCS7/HuR/FOXM1 Signaling Axis Inhibited High-Grade Serous Ovarian Carcinoma Progression.

Goserelin Can Inhibit Ovarian Cancer Proliferation and Simultaneously Protect Ovarian Function from Cisplatin: an in Vitro and in Vivo Study.

The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death

Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer

Hyperoside protects against cyclophosphamide induced ovarian damage and reduced fertility by suppressing HIF-1α/BNIP3-mediated autophagy

Anti-neoplastic effect of heterophyllin B on ovarian cancer via the regulation of NRF2/HO-1 in vitro and in vivo

Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention

GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer

Abstract 6877: Progesterone promotes immunosuppression in the murine mammary gland by causing T cell death

Progesterone inhibits endometrial cancer growth by inhibiting glutamine metabolism through ASCT2

Chitosan Oligosaccharides Alleviate H2O2-stimulated Granulosa Cell Damage via HIF-1α Signaling Pathway

FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest